- Home
- WDI vs VALN Comparison
WDI vs VALN Comparison
Compare WDI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- VALN
- Stock Information
- Founded
- WDI 2021
- VALN 2012
- Country
- WDI United States
- VALN France
- Employees
- WDI N/A
- VALN N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WDI Finance
- VALN Health Care
- Exchange
- WDI Nasdaq
- VALN Nasdaq
- Market Cap
- WDI 775.8M
- VALN 669.2M
- IPO Year
- WDI N/A
- VALN 2021
- Fundamental
- Price
- WDI $15.08
- VALN $11.53
- Analyst Decision
- WDI
- VALN Strong Buy
- Analyst Count
- WDI 0
- VALN 3
- Target Price
- WDI N/A
- VALN $15.33
- AVG Volume (30 Days)
- WDI 192.6K
- VALN 96.9K
- Earning Date
- WDI 01-01-0001
- VALN 08-12-2025
- Dividend Yield
- WDI 11.80%
- VALN N/A
- EPS Growth
- WDI N/A
- VALN N/A
- EPS
- WDI 1.12
- VALN N/A
- Revenue
- WDI N/A
- VALN $230,566,060.00
- Revenue This Year
- WDI N/A
- VALN $18.61
- Revenue Next Year
- WDI N/A
- VALN $25.07
- P/E Ratio
- WDI $12.82
- VALN N/A
- Revenue Growth
- WDI N/A
- VALN 25.47
- 52 Week Low
- WDI $12.16
- VALN $3.62
- 52 Week High
- WDI $14.69
- VALN $11.53
- Technical
- Relative Strength Index (RSI)
- WDI 58.24
- VALN 77.09
- Support Level
- WDI $14.96
- VALN $10.11
- Resistance Level
- WDI $15.12
- VALN $11.18
- Average True Range (ATR)
- WDI 0.10
- VALN 0.41
- MACD
- WDI 0.00
- VALN 0.35
- Stochastic Oscillator
- WDI 85.19
- VALN 100.00
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.